Announced today the initiation of dosing in a Phase 1 clinical trial of APD811.

announced today the initiation of dosing in a Phase 1 clinical trial of APD811, a novel oral drug candidate uncovered by Arena that targets the prostacyclin receptor for the treating pulmonary arterial hypertension, or PAH. ‘An orally bioavailable prostacyclin receptor agonist could enhance the standard of care for individuals with PAH, a life-threatening disorder,’ said William R. Shanahan, M.D., Arena’s Senior Vice President and Chief Medical Officer. ‘APD811 can be a non-prostanoid compound; in preclinical studies, the oral uptake, half life and efficacy features suggest that it might give improved administration over current prostacyclin receptor therapies.’ This randomized, double-blind and placebo-controlled Stage 1 trial is planned to enroll up to 72 healthful adult volunteers and can evaluate the safety, pharmacokinetics and tolerability of single-ascending doses of APD811.Girls had higher reading ratings than did males in grades 4 and 8 in 2003 and in quality 12 in 2002. Nevertheless, boys had higher math scores than did women in grades 4 and 8 in 2003, and in quality 12 in 2000. In 2003, 87 % of young adults ages 18-24 had completed high school with a diploma or an alternative credential, like a General Education Advancement certificate. The high school completion price has increased somewhat since 1980, when it was 84 %. The proportion of Black-alone, non-Hispanic youth who were neither in college nor working was 10 % in 2004, down from 12 % in 2003. More Black-alone, non-Hispanic youth transferred from the category not really enrolled in school rather than working into the category of signed up for school and not working in 2004.